TLR5: A prognostic and monitoring indicator for triple-negative breast cancer

Dai Shi1, Shanshan Zhao1, Wen Jiang1, Chao Zhang1, Ting Liang1 and Guihua Hou1

Abstract
A novel, highly selective biomarker is urgently needed to predict and monitor triple-negative breast cancer (TNBC) because targeting molecules are not currently available. Although associated with various malignant tumors, the role of toll-like receptor 5 (TLR5) in TNBC remains uncertain. We aimed to define the effects of TLR5 in TNBC to determine whether it could serve as a prognostic and monitoring indicator for TNBC. We established TNBC cell line 4T1 with low TLR5 expression (GFP tag; TLR5−4T1) and with normal TLR5 expression (GFP tag; TLR5+4T1) using lentivirus-shRNA-TLR5 knockdown transfection and negative lentivirus transfection, respectively. Detected by western blot and qPCR, we found knockdown of TLR5 resulted in decreased expression of TLR5 and E-cadherin and increased expression of N-cadherin, vimentin, fibronectin, TRAF6, SOX2, and Twist1, which were related to EMT (epithelial–mesenchymal transition). In addition, downregulation of TLR5 increased the invasion and migration of 4T1 cells in vitro, which were investigated by CCK-8 and wound healing, as well as transwell assay and colony formation. Furthermore, the metastatic ability of TLR5−4T1 cells to the lungs was also increased compared to TLR5+4T1 cells in vivo. To verify the effect of TLR5 as a monitor indicator, mice bearing TLR5+ and TLR5−4T1 tumors injected with 125I-anti-TLR5 mAb or isotype 125I-IgG were assessed by whole body phosphor-autoradiography and fluorescence imaging in vivo. Phosphor-autoradiography of model mice revealed early tumors at 6 days after inoculation with TLR5+4T1, but not TLR5−4T1 cells. Intratumoral accumulation of radioactivity positively correlated with TLR5 expression, and fluorescence imaging in vivo revealed both TLR5+ and TLR5−4T1 tumors. Our results suggested that downregulation of TLR5 in TNBC increased tumor invasiveness and EMT expression via TRAF6 and SOX2 pathway and TLR5 could serve as a prognostic and monitoring indicator for TLR5-positive tumors.

Introduction
Membrane-bound toll-like receptors (TLRs) play key roles in innate and adaptive immunity. They are primarily expressed in some types of immunocytes and recognize conserved pathogen-associated molecular patterns (PAMPs)1-4. Various members of the TLR family play diversified roles in cancer progression and development5-8. For example, positive TLR3 expression indicates a favorable prognosis for patients with neuroblastoma7, and TLR4 overexpression is reduced in squamous cell carcinoma of the skin8. Unlike other TLRs, TLR5 is not expressed in murine macrophages and conventional dendritic cells9, but it is expressed at high levels in some malignancies, such as non-small cell lung cancer10 and NK cells within breast cancer11. Cancer cell proliferation and tumor growth are inhibited by TLR5 signaling12-14, but the underlying mechanism has not been fully elucidated.

Breast cancer is the most common cancer among women, and it is associated with high mortality rates15-17. It can be classified into TNBC (triple-negative breast cancer) and non-TNBC subtypes. The TNBC type accounts for 12–24% of all breast cancers and is more aggressive and prone to metastasis than the non-TNBC type. Current clinical management of breast cancer...
mainly depends on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) genes as molecular markers and therapeutic and prognostic indicators. However, targeted diagnoses and therapy are not currently feasible for TNBC because it does not express ER, PR, and HER2. Radical surgery is still the first choice of treatment for breast cancer, even though metastasis usually appears within a few years. Hence, the identification of new monitoring molecular markers and clarifying the underlying mechanisms are critical for improved prognosis for patients with TNBC.

Traditional computed tomography (CT) and magnetic resonance imaging (MRI) in tumor diagnosis and staging mainly reveal anatomic changes, and these are usually found at the later stages. Noninvasive nuclear molecular imaging is a whole-body scanning modality that is based on metabolism and abnormal function. It is a combination of anatomical and functional imaging and is more suitable for the detection and quantitation of target molecules in tumor tissues. Presently, F-18-deoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is clinically applied to evaluate tumor metabolism. However, 18F-FDG is not specific, which sometimes results in diagnostic inaccuracy. Hence, identifying more effective molecular targets for tumor prognosis and therapy is critical. Many recent studies have shown that some innate molecules participate in tumor development and prognosis, such as colon cancer-associated transcript2 (CCAT2), metastasis and prognosis, and miRNAs (potential prognostic biomarkers in patients with bladder cancer). Molecular imaging has rapidly developed and shown great potential in early tumor diagnosis and treatment based on physical and metabolic changes. Radioisotope-labeled target molecules for breast cancer such as 18F-labeled aptamers of Her2/ErbB2 (human epidermal growth factor receptor 2), 125I/131I-labeled anti ICAM-1 (intercellular cell adhesion molecule-1) antibody and 89Zr-Transferrin, have been developed. However, these target molecules are limited by low selection and tumor expression. We developed a 131I-labeled anti-TLR5 antibody that can indicate allorejection. Here, we aimed to determine whether this radiolabeled antibody could serve as a noninvasive monitoring target for early TNBC using the TNBC cell line, 4T1.

Materials and methods

Mice and reagents

All animal studies proceeded in accordance with protocols approved by the Animal Care and Use Committee of Shandong University. Six-week-old male athymic nude mice (20–22 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). The Lentivirus-shRNA (5′–3′ GCCTCAACTATATCAGTATGG) for TLR5 knockdown and negative-control virus was purchased from GenePharma (Shanghai, China). Anti-vimentin (#5741), anti-N-cadherin (#13116), anti-E-cadherin (#3195), anti-SOX2 (#14962) and anti-GAPDH (#5174) antibodies were purchased from Cell Signaling Technologies (CST; Boston, MA, USA). Anti-TLR5 (#ab168382), anti-fibronectin (#ab45688), anti-TRA6 (#ab33915) and anti-Twist1 (#ab49254) antibodies were purchased from Abcam (Cambridge, UK).

Generation of TLR5 knockdown 4T1 cells

Murine TNBC cell lines 4T1 were obtained from the American Type Culture Collection (ATCC). The cells were seeded in 24-well plates (1 × 10^5/well) and incubated at 37°C in a humidified 5% CO2 atmosphere overnight. The medium was then replaced with negative control virus or Lentivirus-shRNA TLR5 diluted in fresh medium at a ratio of 1:100, and the cells were incubated at 37°C in a humidified 5% CO2 atmosphere for 24 h. Finally, the diluted virus was replaced with fresh medium and incubation proceeded under the same conditions for another 48 h. Thereafter, transfection efficiency was calculated. Transfected cells were filtered out using Puromycin (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China).

Western blot and quantitative PCR (qPCR)

Total protein concentrations for western blot were measured using protein assay kits (Beyotime Biotechnology, Shanghai, China). Total protein (20 μg) was loaded onto gel (Bio-Rad Laboratories, Hercules, CA, USA), along with Chameleon Duo ladder protein marker (SMOBIO, Taiwan, R.O.C). Proteins were resolved by electrophoresis at 80 V for 30 min followed by 100 V for 60 min and transferred onto nitrocellulose membranes. Nonspecific binding was blocked with 5% skim milk in blocking buffer for 2 h at room temperature (20°C) and further incubated overnight at 4°C with 1:1000 diluted rabbit anti-mouse TLR5/vimentin/fibronectin/N-cadherin/E-cadherin/TRA6/Sox2/Twist1 antibodies and 1:10000 diluted rabbit anti-mouse GAPDH antibody. Membranes were washed three times with TBS-Tween 20 (TBS-T), incubated with anti-rabbit IgG antibodies (1:5000) for 2 h at room temperature, then scanned and quantified using a Tanon 4200 imaging system (Tanon Science and Technology Co., Ltd., Shanghai, China).

Total RNA was extracted for qPCR from 4T1 cells using the TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. After determining the RNA concentration, the cDNA first strand was synthesized via TransScript First-Strand cDNA Synthesis SuperMix (TRANSGEN BIOTECH, Beijing, China). The mRNA was then measured using TransStart Tip Green qPCR
SuperMix (TRANSGEN BIOTECH, Beijing, China) with the following forward and reverse primers, respectively:

- TLR5, 5’-GCAGGATCAGGGAAGCTGTCAAC-3’ and 5’-CTCCTGAGGTTACGCT-3’;
- E-cadherin, 5’-AGCCAGTTCTTACCAGAGG-3’ and 5’-CTCCTGACCTTACTGAACTTT-3’;
- N-cadherin, 5’-ACCCAGGAGGTTACAGCCT-3’ and 5’-GGGGATGAGGAATAGAGGCT-3’;
- vimentin, 5’-CTTCCACACGCACTACAGG3’ and 5’-GGGGATGAGGAATAGAGGCT-3’;
- TRAF6, 5’-TAAGGGATGACGGGAAGAG3’ and 5’-GGACACTTTACCCTAGGGAA-3’;
- SOX2, 5’-TTTGTCCAGGAGAAGG-3’ and 5’-CTCCTGGGAAGCGTGTCC-3’;
- Twist1, 5’-GGCAACGCTTAGCAAGATTCA-3’ and 5’-ATCTGGAAGAGCCATGAC-3’.

CCK-8 assays

Cell proliferation was evaluated using CCK-8 assays. TLR5⁺ and TLR5⁻ 4T1 cells (2 × 10⁵ well) were, respectively, seeded in 96-well plates overnight, and the absorbance was measured at 450 nm after 0, 6, 24, 36, and 48 h by using a microplate reader. Experiments were repeated three times.

Flow cytometry

Apoptosis was evaluated by digesting TLR5⁺ and TLR5⁻ 4T1 cells with 0.25% trypsin (without EDTA and phenol red), after which, the cells were sedimented by centrifugation (speed in 800g for 5 min). The cells were washed twice with cold PBS and suspended in 400 μL of 1 × annexin V binding solution at a concentration of 1 × 10⁶/mL. Annexin V-FITC (5 μL) was gently mixed with 10 μL of PI staining solution, incubated at 4 °C for 15 min in darkness, passed through a 200-mesh filter, and immediately analyzed by flow cytometry. Experiments were repeated three times.

Colony formation

TLR5⁺ and TLR5⁻ 4T1 cells (1 × 10³/well) were seeded in six-well plates and the medium was changed every 3–4 days. The plates were incubated at 37 °C in a humidified 5% CO₂ incubator for 24 h. Experiments were repeated three times.

Transwell assays

These assays proceeded in 24-well Transwell units with an 8 μm pore polycarbonate membrane. Matrigel (100 μL; 300 μg/mL) was added to the upper compartment. After overnight starvation, suspended cells were seeded in the upper compartment in serum-free medium, and medium supplemented with 10% FBS as a chemotactrant was placed in the lower compartment. Cells in the upper compartment were removed 24 h later by gentle swabbing. Cells that had migrated to the lower surface of the membrane were stained with crystal violet and counted at 400× magnification in five high power fields. TriPLICATE samples were tested, and the experiment was repeated three times.

Lung metastasis experiment

Mice were injected with 1 × 10⁶ TLR5⁺ or TLR5⁻ 4T1 cells via the tail vein, and the mouse lungs were weighed 20 days later and dissected for hematoxylin and eosin (H&E) staining and fluorescence imaging. The experiment was repeated at least three times.

4T1 breast cancer-bearing mice model

All animal studies proceeded in accordance with protocols approved by the Animal Care and Use Committee of Shandong University. Subcutaneous TLR5⁺ and TLR5⁻ 4T1 tumor cells were induced in 6-week-old nude male mice, respectively, by injecting their lower left and right flanks with 1 × 10⁶ TLR5⁺ 4T1 and TLR5⁻ 4T1 cells suspended in 200 μL of PBS. The tumors on mice were monitored every other day. The tumor-bearing mice were assessed by phosphor-autoradiography and fluorescence imaging, and biodistribution was also determined.

Preparation of ¹²⁵I-anti-TLR5 mAb and ¹²⁵I-IgG

We prepared ¹²⁵I-anti-TLR5 and ¹²⁵I-IgG as described previously. A 1:2 (v/v) mixture of 0.9% saline and methanol served as an unfolding agent. The stability of ¹²⁵I-anti-TLR5 mAb and ¹²⁵I-IgG in PBS was evaluated using paper chromatography in PBS and murine serum, then radioactivity was determined using a Gamma counter. Competitive binding was assessed in TLR5⁺ and TLR5⁻ 4T1 cells (5 × 10⁵/well) seeded in 24-well plates with 0.1–1000 nM anti-TLR5 mAb and 10 nM ¹²⁵I-anti-TLR5 mAb and incubated at 37 °C for 45 min. The supernatants were discarded, and then the cells were washed twice with iced 1 × PBS containing 0.1% BSA and harvested for radioactivity determination using a Gamma counter.

Dynamic whole-body phosphor-autoradiography

Three days before radiotracers injection, 3% potassium iodide was added to the drinking water of the mice to
block iodine uptake by the thyroid gland. Tumor-bearing mice (total \( n = 50 \), \( n = 25 \) per group, randomly divided) were each injected with 0.37 MBq of \( ^{125}\text{I}-\text{anti-TLR5 mAb} \) (0.38 \( \mu \text{g} \)) or \( ^{125}\text{I}-\text{IgG} \) (0.38 \( \mu \text{g} \)) via the tail vein. Whole-body phosphor-autoradiography scanning proceeded on day 6, 8, 10, 12, and 14 after tumor cell inoculation (at 48 h after the \( ^{125}\text{I}-\text{anti-TLR5} \) or \( ^{125}\text{I}-\text{IgG} \) injections), respectively. For the blocking group (\( n = 5 \), randomly divided), mice were injected with unlabeled anti-TLR5 mAb (100 \( \mu \text{g} \)) 30 min before the \( ^{125}\text{I}-\text{anti-TLR5} \) mAb (0.37 MBq, 0.38 \( \mu \text{g} \)) injection. Whole-body phosphor-autoradiography scanning proceeded on day 12 after tumor cell inoculation (at 48 h after the \( ^{125}\text{I}-\text{anti-TLR5} \) injections). Mice anesthetized with sodium pentobarbital (0.6%) were placed supine on a storage phosphor screen plate (back to the plate) and left for 20 min in darkness. Plate was then transferred to a Cyclone Plus scanner (PerkinElmer). Manually drawn rectangular regions of interest (\( n = 5 \)) within the target area at each time point were semi-quantified. Digital light units (DLU)/mm\(^2\) were obtained using OptiQuant\textsuperscript{TM} image analysis software 5.0 (PerkinElmer). Tumors were individually stripped and imaged.

**Fluorescence imaging**

The 4T1 cells were transfected with lentivirus-TLR5 knockdown, and the lentivirus expressed green fluorescent protein (GFP) after integration into 4T1 cells. Subcutaneous TLR5\(^-\) and TLR5\(^+\) 4T1 tumors were induced as described above with TLR5\(^-\) 4T1 and TLR5\(^+\) 4T1 cells injected into the lower right and left flanks, respectively, and 4T1 cells without Lentivirus transfection were injected into the back. The mice were anesthetized on day 6, 8, 10, 12, and 14 after tumor cell inoculation, respectively, then the skin on the surface of the tumors was peeled, and the mice were placed prone on the imaging plate and photographed using IVIS Spectrum (PerkinElmer).

**Biodistribution studies**

Three days before injecting the radiotracers, 3% potassium iodide was added to the drinking water of the mice to block iodine uptake of the contralateral muscle. The experiment was repeated three times.

**H&E and immunohistochemical staining**

Tumor-bearing mice (\( n = 5 \)) were sacrificed 72 h after completing whole-body phosphor-autoradiography. Tumors were isolated for immunohistochemical staining with rabbit polyclonal TLR5 antibody (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China) and DAB chromogen (Biogenics Inc., Napa, CA, USA). Immunohistochemistry proceeded using SP-9002 Histostain\textsuperscript{TM} Plus kits (ZSGB-BIO, Beijing, China) according to the manufacturer’s protocols. Sections on slides were visualized at 200\( \times \) and 400\( \times \) magnification. Corresponding positive areas of sections were analyzed (five fields per slide) using Image-Pro Plus software version 4.5.0.29 (Media Cybernetics Inc., Rockville, MD, USA). The experiment was repeated five times.

**Statistical analysis**

Data were presented as the means \( \pm \) standard deviation (SD) derived from at least three independent experiments. Student \( t \) tests were applied using Graph Pad Prism version 5 (GraphPad Software Inc., La Jolla, CA, USA). Significant differences were considered at \( \ast \text{P} < 0.05 \) and \( \ast\ast \text{P} < 0.01 \).

**Results**

**TLR5 downregulation prompted epithelial–mesenchymal transition (EMT) in 4T1 cells**

We quantified the protein and mRNA expression of TLR5, E-cadherin, N-cadherin, vimentin, fibronectin, TRAF6, SOX2 and the transcription factor, Twist1, by western blot and qPCR to verify the effects of TLR5 on EMT (Fig. 1a and b, respectively). The protein expression of E-cadherin significantly decreased after TLR5 downregulation, whereas those of vimentin, fibronectin, N-cadherin, TRAF6, SOX2 and Twist1 increased. The trend in mRNA levels was similar. These results suggested that TLR5 downregulation induced EMT increasing via TRAF6 and SOX2 pathway in TNBC.

**TLR5 downregulation prompted 4T1 tumor cell proliferation, colony formation, and migration in vitro**

We initially determined the survival of patients with breast cancer according to TLR5 gene data using Kaplan–Meier plotter (http://kmplot.com/analysis/) and found significantly worse survival rates among patients with low TLR5 expression in tumors (Fig. 2a). Thereafter, CCK-8 assays showed that the ability to proliferate was higher for TLR5\(^-\) 4T1 than for TLR5\(^+\) 4T1 cells. The OD (450 nm) of TLR5\(^-\) 4T1 vs. TLR5\(^+\) 4T1 cells at 6, 12, 24, 36, and 48 h were 0.27 \( \pm \) 0.01 vs. 0.26 \( \pm \) 0.03, 0.28 \( \pm \) 0.01 vs. 0.35 \( \pm \) 0.02, 0.78 \( \pm \) 0.04 vs. 1.01 \( \pm \) 0.09, 1.19 \( \pm \) 0.06 vs.
1.60 ± 0.05, and 1.78 ± 0.08 vs. 2.26 ± 0.07, respectively (Fig. 2b). Apoptosis in TLR5-downregulated 4T1 cells did not significantly change compared with the negative control (Fig. 2c, P > 0.05). We evaluated the ability of 4T1 cells to form tumors using colony formation assays to further determine the effects of TLR5 on tumor cell proliferation. Figure 2d shows that significantly more colonies were formed by TLR5− 4T1 than by TLR5+ 4T1 cells, indicating higher tumorigenicity. The colony formation rates of TLR5+ 4T1 and TLR5− 4T1 cells were 76 ± 8% vs. 59 ± 4% (P < 0.05), respectively. We verified differences in migration and invasiveness between TLR5+ 4T1 and TLR5− 4T1 cells using wound healing and transwell assays. The migration area was larger in the TLR5− 4T1, than the TLR5+ 4T1 group, and the migration area ratio of TLR5+ vs. TLR5− 4T1 cells was 71.67 ± 3.05% vs. 55.33 ± 3.51% (P < 0.01; Fig. 2e). Transwell invasion assays showed that the number of migrated cells was remarkably lower in the TLR5+ 4T1 group than in the TLR5− 4T1 group (35 ± 5 vs. 82 ± 15 cells/area; P < 0.01; Fig. 2f).

**TLR5 downregulation promoted 4T1 metastasis in vivo**

At 21 days after injecting TLR5− 4T1, TLR5− 4T1 and non-transfected 4T1 cells via the tail vein, the lungs were stripped from the mice, weighed, and assessed by fluorescence imaging and histological analysis. Figure 3a shows much larger green fluorescence areas indicating metastatic sites in the TLR5− 4T1 than in the TLR5+ 4T1 group, and green fluorescence was absent in the non-transfected 4T1 group. The lungs were the heaviest, averaging ~280 mg and reaching 300 mg, in the TLR5− 4T1 groups, whereas normal lungs weighed approximately 120 mg (Fig. 3b). Differences were quite apparent among the three groups (P < 0.05). Staining with H&E revealed typical tumor tissues changes within the lungs where fluorescence imaging positively. Tumor cells that metastasized to the lungs were closely arranged and had larger nuclei than those in normal lung tissues. The number and size of metastases were significantly smaller in the TLR5− 4T1 than in the TLR5+ 4T1 group (Fig. 3c).

**Successful preparation of 125I-anti-TLR5 mAb and 125I-IgG**

The radiochemical purity of 125I-anti-TLR5 mAb and 125I-IgG was both >90%. Both tracers were stable at >95% up to 72 h and relatively stable in serum and normal saline with no detectable significant differences between them (Fig. 4a and B). Competitive binding analysis using >500-fold excess of unlabeled anti-TLR5 mAb almost completely blocked 125I-anti-TLR5 mAb (~5%) binding, with nonspecific binding for 125I-IgG being ~2% (Fig. 4c).

**Dynamic phosphor-autoradiography and fluorescence imaging in vivo**

Dynamic phosphor-autoradiography and fluorescence imaging proceeded on day 6, 8, 10, 12, and 14 after the mice were subcutaneously injected with TLR5+ 4T1 and TLR5− 4T1 cells and at 48 h after injecting them with 125I-anti-TLR5 mAb (Fig. 5a). Whole-body phosphor-autoradiography showed higher and lower radioactivity uptake by TLR5+ 4T1 and TLR5− 4T1 tumors, respectively, at all time points. Dynamic phosphor-autoradiography on day 6 clearly showed TLR5+ 4T1 tumors, whereas TLR5− 4T1 tumors were unclear. However, fluorescence imaging on day 6 clearly showed the location and boundary of TLR5− 4T1 tumors, which might be due to the high specificity of 125I-anti-TLR5 mAb binding. The radioactivity (DLU/mm2) was 6.67-fold higher in TLR5− 4T1 than in TLR5+ 4T1 tumors (141,525 ± 8554 vs. 21,254 ± 2257 cpm). Autoradiography and fluorescence double imaging confirmed that TLR5 was a good reporter for noninvasive monitor and predictor of TNBC. Tumors were not obvious in specifically blocked and 125I-IgG groups at any checked time point,
Fig. 2 TLR5 downregulation enhanced 4T1 tumor cell proliferation, migration and invasiveness in vitro. Kaplan–Meier plotter online tools were used to identify that the patients suffered from breast cancer with low TLR5 expression had a significantly worse survival rate (a). CCK-8 assay showed that TLR5− 4T1 cells have higher proliferation ability than TLR5+ 4T1 cells (b). No difference in apoptosis change in TLR5 downregulated 4T1 cells was detected compared with negative control group (c). The colony formation ability of TLR5− 4T1 cells was significantly increased than TLR5+ 4T1 cells (d). The migration area of TLR5− 4T1 group was larger than TLR5+ 4T1 group (e). The number of migrated cells was remarkably reduced in TLR5+ 4T1 group than TLR5− 4T1 group (f). The data were presented as the means ± SD (n = 3) from three independent experiments, analyzed by Student’s t test. *P < 0.05, **P < 0.01.

Fig. 3 TLR5 downregulation promoted lung metastasis of 4T1 in vivo. Fluorescence images of stripped lungs of mice models: naive 4T1 (no Lentivirus transfection), TLR5+ 4T1 (with negative Lentivirus transfection) and TLR5− 4T1 (with Lentivirus-shRNA TLR5 knockdown transfection) (a). Lungs from untreated mice, TLR5+ 4T1 and TLR5− 4T1 model mice were weighed (b) and H&E staining was performed (c) (n = 3, ***P < 0.01). Representative results of three independent experiments were reported. The data were presented as the means ± SD. The data were analyzed by Student’s t test. *P < 0.05, **P < 0.01.
suggesting specific $^{125}$I-anti-TLR5 mAb accumulation in TLR5-positive tumors (Fig. 5b). Furthermore, to confirm that tumor fluorescence was GFP-tagged, transfected, virus-derived, and TLR5-specific, we inoculated mice with three types of tumor cells. The 4T1 tumors on the right and left flanks were transfected with lentivirus-TLR5 knockdown and negative-control Lentivirus, respectively, and the 4T1 tumor on the back was not transfected. Figure 5c clearly showed tumors in both flanks, whereas the non-transfected 4T1 tumor appeared black.

**Tumor imaging ex vivo**

Radioactivity accumulation was higher in isolated TLR5$^+$ 4T1 than in TLR5$^-$ 4T1 tumors visualized by imaging ex vivo (Fig. 6a). Furthermore, the weight and volume were much larger for TLR5$^-$ 4T1 than for TLR5$^+$ 4T1 tumors (Fig. 6b, c; $P < 0.05$).

**Biodistribution studies**

To validate the imaging results and further quantify $^{125}$I-antiTLR5 mAb uptake at 24, 48, and 72 h, biodistribution studies in vitro proceeded 14 days after TLR5$^+$ 4T1 and TLR5$^-$ 4T1 tumor cell inoculation. Table 1 showed that the T/NT (target to non-target) ratio was the highest in TLR5$^+$ 4T1 tumors at 48 h. Targeting by the $^{125}$I-antiTLR5 mAb was more efficient in TLR5$^+$ 4T1 than in TLR5$^-$ 4T1 tumors. The uptake of $^{125}$I-antiTLR5 mAb in TLR5$^+$ 4T1 tumors at 24, 48, and 72 h post-
injection were 7.73 ± 0.75, 4.92 ± 0.36, and 2.58 ± 0.18 (%ID/g), respectively, with T/NT ratios of 6.84 ± 1.04, 8.41 ± 0.91, and 7.15 ± 1.8, respectively, whereas 125I-antiTLR5 mAb uptake in TLR5− 4T1 tumors was 1.39 ± 0.1, 0.70 ± 0.05, and 0.42 ± 0.03 (%ID/g), respectively, with T/NT ratios of 1.16 ± 0.06, 1.21 ± 0.15, and 1.15 ± 0.13, respectively. The T/NT ratio of the 125I-antiTLR5 mAb was significantly lower for TLR5− 4T1 than for TLR5+ 4T1 tumors. In addition, that of 125I-IgG was only 1.48 ± 0.23 at 48 h, suggesting nonspecific 125I-IgG tumor binding. In the block group, the 125I-anti-TLR5 mAb uptake of TLR5+ 4T1 tumor was only 1.67 ± 0.14 %ID/g at 48 h, suggesting that 125I-antiTLR5 binding with tumor was blocked by unlabeled anti-TLR5 mAb pre-injection in vivo. At 48 h, the T/L (tumor to liver), T/K (tumor to kidney), and T/B (tumor to blood) ratios were significantly higher for the TLR5+ 4T1 tumor than for the TLR5− 4T1 tumor (1.70 ± 0.18 vs. 0.24 ± 0.02, 1.68 ± 0.28 vs. 0.24 ± 0.04, and 1.73 ± 0.12 vs. 0.25 ± 0.02, respectively; *P < 0.01 for all). Background radioactivity in all other organs and tissues was minimal, which was in agreement with the imaging data.

Table 1 Biodistribution of 125I-anti-TLR5 mAb in TLR5+ and TLR5− 4T1 tumor models group.

| Time (h) | 24      | 48      | 72      |
|---------|---------|---------|---------|
| Blood   | 4.47 ± 0.55 | 2.87 ± 0.41 | 1.42 ± 0.12 |
| Thyroid | 2.28 ± 0.13 | 1.15 ± 0.31 | 1.46 ± 0.40 |
| Heart   | 2.02 ± 0.32 | 1.63 ± 0.09 | 1.15 ± 0.12 |
| Lung    | 5.00 ± 0.87 | 1.31 ± 0.31 | 1.23 ± 0.14 |
| Liver   | 7.56 ± 0.71 | 2.91 ± 0.23 | 2.05 ± 0.12 |
| Spleen  | 4.05 ± 0.99 | 0.86 ± 0.07 | 0.66 ± 0.11 |
| Kidney  | 8.36 ± 1.02 | 3.02 ± 0.77 | 1.38 ± 0.20 |
| Intestines | 1.41 ± 0.20 | 0.54 ± 0.22 | 0.59 ± 0.37 |
| Bone    | 0.85 ± 0.26 | 0.61 ± 0.15 | 0.29 ± 0.05 |
| Muscle  | 1.20 ± 0.14 | 0.59 ± 0.11 | 0.37 ± 0.06 |
| Tumor(TLR5+) | 7.73 ± 0.75** | 4.92 ± 0.36** | 2.58 ± 0.18** |
| Tumor(TLR5−) | 1.39 ± 0.10 | 0.70 ± 0.05 | 0.42 ± 0.03 |

125I radiolabeled sodium iodide, h hours
**P < 0.01 compared to the TLR5+ 4T1 tumor and the TLR5− 4T1 tumor in the same mouse. Data are presented as a mean percent injected dose per gram (%ID/g) ± standard deviation (Mean ± SD) of five animals.

H&E and immunohistochemical staining

Figure 7a, c show representative microscopy images of TLR5+ 4T1 and TLR5− 4T1 tumor sections (5-μm-thick) stained with H&E (100× and 400× magnification) and immunohistochemically stained for TLR5 (200× and 400× magnification) (Fig. 7b, d). Staining with H&E showed typical changes in tumor tissues. The surface and cytoplasm of tumor cells were immunohistochemically stained brown indicating TLR5 positivity. The ratio of positively stained tumor cells was much higher for TLR5+ 4T1 than for TLR5− 4T1 tumors (n = 5; 68.75 ± 5.25% vs. 20.65 ± 5.65%, P < 0.01).

Discussion

This study showed that TLR5 downregulation prompted TNBC proliferation, metastasis, and invasion, in vitro
and in vivo. More importantly, we found that TLR5 on TNBC could potentially serve as a reporter for lower metastasis, lower invasion, and better prognosis. Our results revealed a novel target molecule for earlier TNBC detection and prognosis prediction, and this could provide the means for new strategies to monitor and predict TLR5-positive tumors.

Dynamic interactions between tumors and their microenvironments are essential for tumor growth, angiogenesis, and metastasis. High levels of TLR5 were expressed during intestinal epithelial cell-mediated antitumor activity in a mouse xenograft model of human colon cancer. Our findings are consistent with these results. To understand whether the downregulation of TLR5 could promote breast cancer metastasis and invasion, we detected EMT markers and its signal pathway, TRAF6 and SOX2. The EMT represented a fatal transfer of cancer progression. Twist1, a transcription factor, played a key role in cancer development and progression and up-regulated Twist1 induced EMT and E-cadherin repression, indicating that Twist1 promoted metastasis by inducing EMT. Using western bolt and qPCR, we found E-cadherin and TLR5 expression decreased in TLR5− 4T1 cells, whereas vimentin, fibronectin, N-cadherin and Twist1 expression increased. The metastatic and invasive abilities of TLR5− 4T1 cells were enhanced.

Results might help to further understand why downregulated TLR5 expression promoted 4T1 cell proliferation, metastasis, and invasion. Our data in vitro showed that TLR5 expressed in breast cancer could serve as a reporter of cancer invasiveness.

Bioprospecting for target molecules represents a promising solution for cancer prognosis. TNBC is associated with aggressive tumor behavior and a worse prognosis. However, the early discovery of TNBC is particularly important, since its onset, early metastasis, and aggressive invasiveness is coupled with a lack of targeted therapy. Therefore, identifying novel targets that closely correlate with TNBC progression is of considerable importance for its monitor and prognosis.

We previously correlated TLR5 expression with allograft rejection. The expression of TLR5 in NK cells from patients with breast cancer has recently been discovered, and TLR5 expression could restrain tumor growth and metastasis in vitro and in vivo. Based on these findings, we postulated that TLR5 in TNBC cells might play an important role in the progression of TNBC and serve as a novel target suitable for early TNBC monitor and prediction.

Targeted radioimmunoimaging with monoclonal antibodies against many kinds of cancers has been successful. Radiolabeled 125I-antiTLR5 mAb might provide a means of visualizing TLR5 expression in vivo. Our data suggested that 125I-antiTLR5 mAb, which is clinically relevant, can be used in TNBC tumor models.

Our results in vitro indicated that TLR5 in TNBC was closely associated with cell invasion, but whether the same
behavior retained in vivo remains unknown. We therefore established a xeno-subcutaneous tumor model using nude mice, then monitored with an $^{125}$I-labeled anti-TLR5 mAb tracer, which was with high affinity for TLR5 in 4T1 cells in vitro. The distribution in vitro and results of whole-body phosphor-autoradiography in vivo revealed much higher radiotracer retention in TLR5$^{+}$ 4T1 than in TLR5$^{-}$ 4T1 tumors at all time points. The $^{125}$I-antiTLR5 mAb could not target TLR5$^{+}$ 4T1 tumor in group of pre-injecting unlabeled anti-TLR5 mAb, and tumors were not visualized by radiography, thus, confirming the specificity of $^{125}$I-antiTLR5 mAb imaging.

Fluorescent reporter gene imaging in vivo has been applied to detect the growth and migration of labeled cells in many kinds of diseases. Here, we monitored tumor locations using a TLR5 knockdown 4T1 cell line labeled with green fluorescent protein. The fluorescence images of virus-transfected 4T1 tumors were much clearer than those of non-transfected 4T1 tumors. Moreover, this method had the advantage of clearly displaying tumor margins. More importantly, we found that locations of fluorescence emission contained more tracer radioactivity in TLR5$^{+}$ 4T1 tumor, which further confirmed that tumor imaging was TLR5 expression-specific. Additionally, early images showed the TLR5$^{-}$ 4T1 tumors were larger than TLR5$^{+}$ 4T1 tumors, which suggested that TLR5 expression might inhibit tumor growth in vivo.

To confirm that TLR5 affects tumor metastasis, we established lung metastasis mouse models by injecting TLR5$^{+}$ 4T1 and TLR5$^{-}$ 4T1 cells via tail veins, and evaluated the findings using fluorescence imaging. The results showed much clearer lung tumors in TLR5$^{+}$ 4T1 group than in TLR5$^{+}$ 4T1 group, suggesting that TLR5 negatively affected TNBC metastasis.

These data suggested that TLR5 expressed in breast cancer could be considered as a biomarker in vivo for the noninvasive molecular imaging of TNBC. It could also be used to monitor tumor development and metastasis, predict its prognosis, evaluate therapy responses, and as a target for therapy. Low tracer uptake in the lungs and heart, and high uptake in tumors increased image contrast. These cell-specific and favorable non-target clearance features of $^{125}$I-antiTLR5 mAb rendered it a promising radiotracer for TNBC imaging.

This study had some limitations. The molecular weight of labeled antibodies was too high for clinical applications. This might be overcome by reducing extended circulation by selecting antibody fragments, adapters, or other small molecules that specifically bind to TLR5. A radioisotope-labeled TLR5-targeting probe suitable for clinical application, such as iodine 131 or the positron nuclide Fluoro-18, should be further investigated. Hence, additional analyses of TLR5 on breast cancer in vitro and in vivo are required.

In conclusion, the downregulation of TLR5 in TNBC increased tumor invasiveness and EMT expression and promoted TNBC metastasis. Therefore, TLR5 might be useful for monitoring and evaluating TNBC prognosis and serve as a novel target for the early detection of TNBC and other TLR5-positive tumors. The radioisotope-labeled probe, $^{125}$I-antiTLR5 mAb, could potentially serve as an ideal noninvasive monitoring agent for TLR5-positive tumors.

Acknowledgements
This study was supported by grants from the National Natural Science Foundation of China (81371601, to G.H.) and the Natural Science Foundation of Shandong Province (ZR2019MH019, to G.H.)

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-019-2187-8).

Received: 17 September 2019 Revised: 3 December 2019 Accepted: 4 December 2019
Published online: 18 December 2019

References
1. Akira, S. Toll-like receptor signaling. J. Biol. Chem. 34, 38105–38108 (2003).
2. Jie-Jie, S. et al. Activation of toll pathway is different between kuruma shrimp and Drosophila Front. Immunol. 8, 1151 (2017).
3. Cytor, J. C. & Mellors, J. W. Toll-like receptor agonists: can they act a toll on human immunodeficiency virus persistence? Clin. Infect. Dis. 64, 1696–1698 (2017).
4. Krieg, A. M. & Vollmer, J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunological Rev. 220, 251–269 (2010).
5. Kluwe, J., Mencin, A. & Schwabe, R. F. Toll-like receptors, wound healing, and carcinogenesis. J. Mol. Med. 87, 125–138 (2009).
6. Rakoff-Nahoum, S. & Medzhitov, R. Toll-like receptors and cancer. Nature Rev. Cancer 9, 57–63 (2008).
7. Lin, L. L. et al. Downregulation of c-Myc is involved in TLR3-mediated tumor death of neuroblastoma xenografts. Lab. Investig. 96, 719–30 (2016).
8. Iotzova-Weiss, G. et al. TLR4 as a negative regulator of keratinocyte prolifera-
tion. PLoS ONE 12, e0185667 (2017).
9. Cai et al. Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71, 2466–2475 (2011).
10. Zhou et al. Expression of TLR5 in different types of non-small cell lung cancer cell lines and its activation mechanism. Chin. J. Lung Cancer 18, 8–15 (2015).
11. Shuang, C. et al. Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility. Oncotarget 8, 88622–88629 (2017).
12. Burdelya, L. G. et al. Central role of liver in anticancer and radioprotective
activities of Toll-like receptor 5 agonist. Proc. Natl Acad. Sci. 110, E1857–E1866 (2013).
13. Li, W. et al. CLBL502, an agonist of toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro. Int. J. Biol. Macromol. 82, 97–103 (2015).
14. O’Neill, L. A. J., Bryant, C. E. & Doyle, S. L. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177–197 (2009).
15. Aksam, M., Iqbal, M., Daniyal, M. & Khan, A. U., Awareness and current knowledge of breast cancer. Biol. Res. 50, 33 (2017).
16. Eniu, A. et al. Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. Cancer 113, 2269–2281 (2008).
17. Siegel, R, Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–39 (2013).
18. Joyce, D. P. et al. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Surgeon 15, 272–277 (2016).
19. Bertazzi, N., Pesce, M., Santt, P. L. & Raposo, E. Oncoplastic breast surgery: comprehensive review. Eur. Rev. Med. Pharmacol. Sci. 21, 2572–2585 (2017).
20. Majumder, S. & Chari, S. T. Chronic pancreatitis. Wiadomosci Lekarskie 387, 1957–1966 (2016).
21. Ou, X. et al. Ability of 18F-FDG PET/CT radiomic features to distinguish breast carcinoma from breast lymphoma. Contrast Med. Imaging 2019, 4507694 (2019).
22. Wang, D. et al. Long noncoding RNA CCAT2 as a novel biomarker of metastasis and prognosis in human cancer: a meta-analysis. Oncotarget 8, 75664–75674 (2017).
23. Peng, F. et al. Identification of a three miRNA signature as a novel potential prognostic biomarker in patients with bladder cancer. Oncotarget 8, 105553–105560 (2017).
24. Jhan, J. R. & Andrechek, E. R. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 18, 1595–1609 (2017).
25. Kim, H. J. et al. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE 14, e0211047 (2019).
26. You, L., Wang, X. & Guo, Z. MicroSPECT imaging of triple negative breast cancer cell tumor xenograft in athymic mice with radiolabeled anti-ICAM-1 monoclonal antibody. Appl. Radiat. Isot. 139, 20–25 (2018).
27. Henry, K. E. et al. Non-invasive 89Zr-transferrin PET shows improved tumor targeting compared to 18F-FDG PET in MYC-overexpressing human triple negative breast cancer. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 59, 61–57 (2017).
28. Sun, H. et al. Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb. J. Cell. Mol. Med. 18, 2437–2444 (2014).
29. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
30. Rhee, S. H., Im, E. & Pottholakul, C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135, 518–528 (2008).
31. Wang, N. et al. miR520c blocks EMT progression of human breast cancer cells by repressing STAT3. Oncol. Rep. 37, 1537–1544 (2017).
32. Zhao, Z., Rahman, M. A., Chen, Z. G. & Shin, D. M. Multiple biological functions of Twist1 in various cancers. Oncotarget 8, 20380–20393 (2017).
33. Yuan, W. et al. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget 7, 29507–29519 (2016).
34. Chen, L. et al. TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. J. Cell. Mol. Med 22, 1337–1349 (2018).
35. Liu, X. et al. Sox2 promotes tumor aggressiveness and epithelial-mesenchymal transition in tongue squamous cell carcinoma. Int. J. Mol. Med. 42, 1418–1426 (2018).
36. Wang, Y., Zhou, J., Wang, Z., Wang, P. & Li, S. Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion. Biochem. Biophys. Res. Commun. 493, 429–436 (2017).
37. Wang, D. et al. Long noncoding RNA CCAT2 as a novel biomarker of metastasis and prognosis in human cancer: a meta-analysis. Oncotarget 8, 75664–75674 (2017).
38. van Dongen, G. A., Visscher, G. W., Lub-de Hooge, M. N., de Vries, E. G. & Perk, L. R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 12, 1379–1389 (2007).
39. Agarwal, G. et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: does the survival vary for all stages? World J. Surg. 40, 1362–1372 (2016).
40. Wein, L. & Loi, S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast 34, 27–30 (2017).
41. Rampurwala, M., Wisinski, K. B. & Ruth, O. R. Role of the androgen receptor in triple-negative breast cancer. Clin. Adv. Hematol. Oncol. 14, 186–193 (2016).
42. Narandes, S., Huang, S., Murphy, L. & Xu, W. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC). BMC Cancer 18, 22 (2018).
43. Brackett, C. M. et al. Toll-like receptor-5 agonist, entomolmod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc. Natl. Acad. Sci. USA 113, E874–E883 (2016).
44. Zhou, H. et al. High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 140, 633–643 (2014).
45. Ogawa, M. & Takakuza, H. In vivo molecular imaging for biomedical analysis and therapies. Anal. Sci. 34, 273–281 (2018).